SCHEMBL4378530

SCHEMBL4378530

COc1cccc(C=CC(=O)N2CCN(c3ccncc3)CC2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.64
CYP1A1 P04798 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP1B1 Q16678 1/20 0.59
ALDH1A1 P00352 3/20 0.58
GAA P10253 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
ROCK2 O75116 1/20 0.56
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 1/20 0.52
HTT P42858 1/20 0.52
ME2 P23368 1/20 0.51
ME1 P48163 1/20 0.51
ME3 Q16798 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190944 1.00 ACHE (0.64) ACHECYP1A1CYP1A2CYP2D6CYP1B1
SCHEMBL4377401 0.90 ACHE (0.58) ACHECYP1A1CYP1A2CYP2D6CYP1B1
SCHEMBL14190917 0.90 ACHE (0.58) ACHECYP1A1CYP1A2CYP2D6CYP1B1
SCHEMBL14190916 0.81 GAA (0.61) ACHECYP1A1CYP1B1ALDH1A1GAA
SCHEMBL4380520 0.81 GAA (0.61) ACHECYP1A1CYP1B1ALDH1A1GAA
SCHEMBL3115235 0.81 KMT2A (0.64) ACHEALDH1A1MEN1NPC1POLB
SCHEMBL3115230 0.81 KMT2A (0.64) ACHEALDH1A1MEN1NPC1POLB
SCHEMBL11467113 0.80 ACHE (0.57) ACHECYP1A1CYP1A2CYP2D6CYP1B1
SCHEMBL11467112 0.80 ACHE (0.57) ACHECYP1A1CYP1A2CYP2D6CYP1B1
SCHEMBL6786109 0.78 ACHE (0.56) ACHEALDH1A1GAATDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 ACHE 1650/4885CYP1A1 1278/4885CYP1A2 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.